Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia
CompanyDeals

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia

CStone Pharmaceuticals (HKG: 2616) announced that it has entered into a collaboration agreement with Kimia Therapeutics, Inc., a biopharmaceutical company focused on innovative oncology and immunology therapies, to jointly advance…

GenFleet's Oral Pan‑RAS Inhibitor GFH276 Clears Multiple CTAs in China and Australia – Innovative Combination Trials Advance Across RAS‑Mutant Solid Tumors

GenFleet’s Oral Pan‑RAS Inhibitor GFH276 Clears Multiple CTAs in China and Australia – Innovative Combination Trials Advance Across RAS‑Mutant Solid Tumors

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Policy / Regulatory

CDE Launches Technical Guidelines for Pediatric Anti-tumor Drug Development

CompanyDrug

Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Gain Clinical Trial Approvals

CompanyDeals

Akeso Biopharma and LaNova Medicines Collaborate on Clinical Studies for Cancer Therapies

CompanyDrug

Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Secure Clinical Trial Approvals for Solid Tumors

CompanyDeals

Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors

Policy / Regulatory

CDE Launches Technical Guidelines for Pediatric Anti-tumor Drug Clinical R&D

CompanyDrug

Sihuan Pharmaceutical’s KM501 Receives Clinical Trial Approval for HER2-Positive Tumors

CompanyDeals

Alphax Bio Raises Millions for Spatial Proteomics and Tumor Immune Microenvironment Research

Show More